Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma
文献类型：期刊论文
| 作者 | Chen, Jing1,2,3; Liu, Tongxin1,2,3; Sun, Quanquan1,2,3; Jin, Ting1,2,3 |
| 刊名 | MEDICINE
 |
| 出版日期 | 2020-07-17 |
| 卷号 | 99 |
| 关键词 | adjuvant chemotherapy concurrent chemoradiotherapy intensity-modulated radiotherapy prognosis stage II nasopharyngeal carcinoma |
| ISSN号 | 0025-7974 |
| DOI | 10.1097/MD.0000000000020443 |
| 通讯作者 | Jin, Ting(jinjin_2019@163.com) |
| 英文摘要 | Background: Although common, the use of concurrent chemoradiotherapy with adjuvant chemotherapy for stage II nasopharyngeal carcinoma (NPC) is controversial due to its undefined clinical benefits. We, therefore, conducted a retrospective cohort study to investigate whether adjuvant chemotherapy confers survival gains to stage II NPC patients. Methods: In this study, we examined whether combining adjuvant chemotherapy (AC) and/or concurrent chemotherapy with radiotherapy (CCRT) improved survival in patients with stage II NPC. Three hundred thirty-five stage II NPC patients were retrospectively analyzed between June 2003 and June 2016 and received CCRT; some patient groups also received AC every 3 weeks for 2 to 3 cycles. Results: The median follow-up duration was 72 months for all patients (range, 26-151 months) and the estimated 5-year locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) rates were 95.1%, 97.8%, 93.5%, and 94.3%. At the last follow-up, there were no statistically significant differences among the CCRT and CCRT+AC groups in 5-year LRRFS (95.2% vs 94.9%,P = .599), DMFS (98.5% vs 92.4%,P = .152), PFS (93.8% vs 90.2%,P = .599), or OS (95.5% vs 93.9%,P = .682) rates. Conclusion: The analyses revealed that a combined regimen was not an independent prognostic factor for any survival outcome. However, patients who received CCRT plus AC experienced more acute adverse events than those who received CCRT alone. Thus, the addition of AC to CCRT did not improve survival outcomes, but was associated with higher incidences of acute treatment-associated toxicities than CCRT alone in patients with stage II NPC. |
| WOS关键词 | RADIOTHERAPY ; PROGNOSIS ; CANCER |
| WOS研究方向 | General & Internal Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000557513600004 |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/44752]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Jin, Ting |
| 作者单位 | 1.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Zhejiang, Peoples R China 2.Univ Chinese Acad Sci, Dept Radiat Oncol, Canc Hosp, Hangzhou, Zhejiang, Peoples R China 3.Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Jing,Liu, Tongxin,Sun, Quanquan,et al. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma[J]. MEDICINE,2020,99. |
| APA | Chen, Jing,Liu, Tongxin,Sun, Quanquan,&Jin, Ting.(2020).Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.MEDICINE,99. |
| MLA | Chen, Jing,et al."Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma".MEDICINE 99(2020). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。